<p><strong>中生北控生物科技</strong> (HKG:8247) 的股票在過去一個月繼續保持其近期的勢頭，漲幅達到了 56%。過去 30 天的表現是該股票在過去一年中 803% 漲幅的錦上添花，實在是令人矚目。</p>
<p>即使在如此大幅的價格上漲之後，中生北控生物科技目前仍可能被視為一個強勁的買入機會，其市銷率（&#34;P/S&#34;）為 3.2 倍，考慮到香港生物科技行業中幾乎一半的公司市銷率超過 14.2 倍，甚至市銷率高達 71 倍的情況也並不罕見。然而，市銷率可能較低是有原因的，需要進一步調查以確定其合理性。</p>
<p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
<p>查看我們對中生北控生物科技的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26051622-ps-multiple-vs-industry-1-dark-2/1771280731031?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26051622-ps-multiple-vs-industry-1-dark-2/1771280731031"/></p>
<p>SEHK:8247 市銷率與行業比較 2026 年 2 月 16 日</p>
<h3>中生北控生物科技近期表現如何？</h3>
<p>例如，中生北控生物科技近期收入的下降值得深思。或許市場認為近期的收入表現不足以跟上行業的步伐，導致市銷率受到影響。如果你喜歡這家公司，你會希望情況不是這樣，以便在它不受歡迎時能夠買入一些股票。</p>
<p>想要了解公司收益、收入和現金流的全貌嗎？那麼我們對中生北控生物科技的 <strong>免費</strong> 報告將幫助你揭示其歷史表現。</p>
<h2>收入增長指標告訴我們關於低市銷率的什麼？</h2>
<p>為了證明其市銷率的合理性，中生北控生物科技需要實現遠低於行業水平的微弱增長。</p>
<p>回顧一下，公司的去年收入增長並不令人興奮，出現了令人失望的 21% 的下降。這意味着在更長的時間內，它的收入也出現了下滑，過去三年總收入下降了 35%。因此，不幸的是，我們必須承認該公司在這段時間內未能有效地增長收入。</p>
<p>與公司相比，行業其他部分預計在明年將增長 650%，這確實讓公司的近期中期收入下降顯得更加突出。</p>
<p>有了這些信息，我們並不感到驚訝中生北控生物科技的市銷率低於行業水平。然而，隨着收入的下滑，市銷率是否已經觸底並沒有保證。如果公司不改善其收入增長，市銷率可能會進一步下降。</p>
<h2>關鍵要點</h2>
<p>中生北控生物科技的股票已經顯著上漲，但其市銷率仍然低迷。一般來説，我們傾向於將市銷率的使用限制在評估市場對公司整體健康狀況的看法。</p>
<p>正如我們所懷疑的，我們對中生北控生物科技的審查顯示，其中期收入的萎縮正在導致其低市銷率，考慮到行業即將增長。在這個階段，投資者認為收入改善的潛力不足以證明更高的市銷率。除非近期的中期條件改善，否則它們將繼續對股價形成障礙。</p>
<p>此外，你還應該瞭解我們發現的 <strong>中生北控生物科技的一個警示信號</strong>。</p>
<p>如果這些 <strong>風險讓你重新考慮對中生北控生物科技的看法</strong>，請查看我們的高質量股票互動列表，以瞭解還有哪些其他選擇。</p>
<h3>估值是複雜的，但我們在這裏為你簡化。</h3>
<p>通過我們的詳細分析，發現中生北控生物科技是否可能被低估或高估，分析內容包括 <strong>公允價值估計、潛在風險、股息、內部交易及其財務狀況。</strong></p>
<p>獲取免費分析</p>

中生北控生物科技

<p>中生北控生物科技（HKG:8247）股票在過去一個月上漲了 56%，使得過去一年總漲幅達到了令人矚目的 803%。儘管如此，該公司的低市銷率（P/S）為 3.2 倍引發了人們的擔憂，因為其收入出現了下降，去年下降了 21%，三年來下降了 35%。生物科技行業預計明年將增長 650%，這突顯了中生北控的困境。投資者仍然保持謹慎，因為低市銷率反映了對未來收入增長的懷疑，可能限制了股價的上漲，除非業績有所改善</p>

<p><strong>Biosino Bio-Technology and Science Incorporation</strong> (HKG:8247) shares have continued their recent momentum with a 56% gain in the last month alone. The last 30 days were the cherry on top of the stock's 803% gain in the last year, which is nothing short of spectacular.</p>
<div class="lb-trans"><p><strong>中生北控生物科技</strong> (HKG:8247) 的股票在過去一個月繼續保持其近期的勢頭，漲幅達到了 56%。過去 30 天的表現是該股票在過去一年中 803% 漲幅的錦上添花，實在是令人矚目。</p>
</div><p>Even after such a large jump in price, Biosino Bio-Technology and Science Incorporation may still look like a strong buying opportunity at present with its price-to-sales (or &#34;P/S&#34;) ratio of 3.2x, considering almost half of all companies in the Biotechs industry in Hong Kong have P/S ratios greater than 14.2x and even P/S higher than 71x aren't out of the ordinary. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>即使在如此大幅的價格上漲之後，中生北控生物科技目前仍可能被視為一個強勁的買入機會，其市銷率（&#34;P/S&#34;）為 3.2 倍，考慮到香港生物科技行業中幾乎一半的公司市銷率超過 14.2 倍，甚至市銷率高達 71 倍的情況也並不罕見。然而，市銷率可能較低是有原因的，需要進一步調查以確定其合理性。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</p>
</div><p>View our latest analysis for Biosino Bio-Technology and Science Incorporation</p>
<div class="lb-trans"><p>查看我們對中生北控生物科技的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/26051622-ps-multiple-vs-industry-1-dark-2/1771280731031" alt="" original-src="https://images.simplywall.st/asset/chart/26051622-ps-multiple-vs-industry-1-dark-2/1771280731031"/></p>
<p>SEHK:8247 Price to Sales Ratio vs Industry February 16th 2026</p>
<div class="lb-trans"><p>SEHK:8247 市銷率與行業比較 2026 年 2 月 16 日</p>
</div><h3>What Does Biosino Bio-Technology and Science Incorporation's Recent Performance Look Like?</h3>
<div class="lb-trans"><h3>中生北控生物科技近期表現如何？</h3>
</div><p>For instance, Biosino Bio-Technology and Science Incorporation's receding revenue in recent times would have to be some food for thought. Perhaps the market believes the recent revenue performance isn't good enough to keep up the industry, causing the P/S ratio to suffer. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>例如，中生北控生物科技近期收入的下降值得深思。或許市場認為近期的收入表現不足以跟上行業的步伐，導致市銷率受到影響。如果你喜歡這家公司，你會希望情況不是這樣，以便在它不受歡迎時能夠買入一些股票。</p>
</div><p>Want the full picture on earnings, revenue and cash flow for the company? Then our <strong>free</strong> report on Biosino Bio-Technology and Science Incorporation will help you shine a light on its historical performance.</p>
<div class="lb-trans"><p>想要了解公司收益、收入和現金流的全貌嗎？那麼我們對中生北控生物科技的 <strong>免費</strong> 報告將幫助你揭示其歷史表現。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The Low P/S?</h2>
<div class="lb-trans"><h2>收入增長指標告訴我們關於低市銷率的什麼？</h2>
</div><p>In order to justify its P/S ratio, Biosino Bio-Technology and Science Incorporation would need to produce anemic growth that's substantially trailing the industry.</p>
<div class="lb-trans"><p>為了證明其市銷率的合理性，中生北控生物科技需要實現遠低於行業水平的微弱增長。</p>
</div><p>Taking a look back first, the company's revenue growth last year wasn't something to get excited about as it posted a disappointing decline of 21%. This means it has also seen a slide in revenue over the longer-term as revenue is down 35% in total over the last three years. So unfortunately, we have to acknowledge that the company has not done a great job of growing revenue over that time.</p>
<div class="lb-trans"><p>回顧一下，公司的去年收入增長並不令人興奮，出現了令人失望的 21% 的下降。這意味着在更長的時間內，它的收入也出現了下滑，過去三年總收入下降了 35%。因此，不幸的是，我們必須承認該公司在這段時間內未能有效地增長收入。</p>
</div><p>In contrast to the company, the rest of the industry is expected to grow by 650% over the next year, which really puts the company's recent medium-term revenue decline into perspective.</p>
<div class="lb-trans"><p>與公司相比，行業其他部分預計在明年將增長 650%，這確實讓公司的近期中期收入下降顯得更加突出。</p>
</div><p>With this information, we are not surprised that Biosino Bio-Technology and Science Incorporation is trading at a P/S lower than the industry. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.</p>
<div class="lb-trans"><p>有了這些信息，我們並不感到驚訝中生北控生物科技的市銷率低於行業水平。然而，隨着收入的下滑，市銷率是否已經觸底並沒有保證。如果公司不改善其收入增長，市銷率可能會進一步下降。</p>
</div><h2>The Key Takeaway</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><p>Shares in Biosino Bio-Technology and Science Incorporation have risen appreciably however, its P/S is still subdued. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.</p>
<div class="lb-trans"><p>中生北控生物科技的股票已經顯著上漲，但其市銷率仍然低迷。一般來説，我們傾向於將市銷率的使用限制在評估市場對公司整體健康狀況的看法。</p>
</div><p>As we suspected, our examination of Biosino Bio-Technology and Science Incorporation revealed its shrinking revenue over the medium-term is contributing to its low P/S, given the industry is set to grow. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. Unless the recent medium-term conditions improve, they will continue to form a barrier for the share price around these levels.</p>
<div class="lb-trans"><p>正如我們所懷疑的，我們對中生北控生物科技的審查顯示，其中期收入的萎縮正在導致其低市銷率，考慮到行業即將增長。在這個階段，投資者認為收入改善的潛力不足以證明更高的市銷率。除非近期的中期條件改善，否則它們將繼續對股價形成障礙。</p>
</div><p>Plus, you should also learn about this <strong>1 warning sign we've spotted with Biosino Bio-Technology and Science Incorporation</strong>.</p>
<div class="lb-trans"><p>此外，你還應該瞭解我們發現的 <strong>中生北控生物科技的一個警示信號</strong>。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Biosino Bio-Technology and Science Incorporation</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果這些 <strong>風險讓你重新考慮對中生北控生物科技的看法</strong>，請查看我們的高質量股票互動列表，以瞭解還有哪些其他選擇。</p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值是複雜的，但我們在這裏為你簡化。</h3>
</div><p>Discover if Biosino Bio-Technology and Science Incorporation might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通過我們的詳細分析，發現中生北控生物科技是否可能被低估或高估，分析內容包括 <strong>公允價值估計、潛在風險、股息、內部交易及其財務狀況。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>獲取免費分析</p>
</div>

中生北控生物科技（HKG:8247）即便股價已上漲 56%，仍因增長乏力而受到制約